Highlights

  • Memphasys shares closed flat at AUD 0.0050 on 20 March 2026 following a business update
  • Operations across the Middle East remain uninterrupted despite geopolitical tensions
  • Continued clinical usage in Qatar supports recurring demand for the Felix System
  • New commercial orders secured in the UAE and Iraq
  • Expansion efforts underway in Egypt and Turkey, with initial orders expected next quarter
  • Stock remains down ~50% over the past year, reflecting sustained investor cautiousness.

Memphasys Ltd (ASX:MEM) ended the session unchanged at AUD 0.0050 on 20 March 2026, coinciding with the release of its latest operational update. While the share price showed no immediate reaction, the stock remains significantly lower over a longer horizon, down 16.67% over the past five days and approximately 50% over the past year, reflecting broader investor caution. The company’s latest update, however, highlights steady progress across its key Middle East and North Africa (MENA) markets.

Stable Operations Despite Challenging Backdrop

Memphasys confirmed that its commercial activities across the MENA region are continuing without disruption, despite ongoing geopolitical instability in certain areas. The company stated that its distribution networks, logistics, and customer engagement remain fully functional, with no material interruptions identified.

This operational continuity appears to underpin current business performance, with demand and order activity tracking in line with expectations. The company’s ability to maintain normal operations in a complex environment reflects the resilience of its commercial framework and partnerships in the region.

Qatar Provides Foundation of Recurring Demand

Qatar continues to represent a key established market for Memphasys, with Hamad Medical Corporation maintaining routine use of the Felix System in clinical procedures. The ongoing utilisation of the system is driving consistent cartridge consumption, which forms an important component of the company’s recurring revenue model.

The continued engagement with a major institutional customer highlights the integration of the technology into clinical workflows and reinforces the stability of demand within the assisted reproductive technology (ART) segment. This steady base of activity is supporting the company’s broader regional expansion strategy.

New Orders Signal Broader Market Engagement

Memphasys reported securing new commercial orders from customers in both the United Arab Emirates and Iraq. These orders indicate ongoing interest at the clinic level and reflect the company’s efforts to expand its presence beyond initial anchor markets.

The addition of new customers across multiple jurisdictions suggests that demand is not concentrated in a single geography. Instead, the company is seeing a more distributed pattern of adoption, which may contribute to a more balanced and scalable commercial profile over time.

These early-stage orders are part of a broader strategy aimed at gradually building recurring demand, particularly through increased usage of consumables associated with the Felix System.

Egypt and Turkey Offer Near-Term Growth Pathways

Beyond its existing markets, Memphasys is advancing its entry into Egypt and Turkey, both of which are viewed as important growth opportunities within the region.

In Egypt, the company has established a reseller partnership and is progressing through regulatory approvals. Early engagement efforts, including industry presentations, have generated interest in the Felix System, with initial trial orders anticipated in the coming quarter. These trial programs are expected to support clinic onboarding and lay the groundwork for wider commercial rollout.

Similarly, in Turkey, regulatory processes are moving forward as planned, with first commercial orders expected once approvals are finalised. The country’s established fertility sector and geographic positioning make it a strategic addition to Memphasys’ regional footprint.

Supply Chain Strength Supports Execution

Memphasys highlighted that its supply chain and distribution network remain fully operational, supported by its partnership with International Technical Legacy (ITL). The company noted that logistics channels are functioning normally, with no delays in delivery or fulfilment reported.

The ability to ship products directly into contracted markets provides flexibility, enabling the company to respond to changing conditions while maintaining consistent supply. This operational readiness is critical as Memphasys continues to expand across multiple jurisdictions.

Diversified Strategy Underpins Regional Expansion

A key feature of Memphasys’ approach in the MENA region is its focus on building demand at the clinic level, rather than relying solely on distributor-driven sales. This strategy is supported by a diversified customer base spanning multiple countries, reducing dependence on any single market.

The company’s ongoing progress—including continued usage in established markets, new order inflows, and regulatory advancements—suggests that its multi-market strategy is gaining traction. By operating across regions at different stages of adoption, Memphasys is positioning itself to capture incremental growth opportunities while managing regional risks.

What This Means for Investors?

Memphasys’ latest update reflects operational stability and continued commercial progress, even as its share price remains subdued over a longer timeframe. The absence of immediate price movement may indicate that investors are awaiting stronger revenue visibility or larger-scale commercial traction.

However, the combination of steady demand in Qatar, new orders from additional markets, and expansion into Egypt and Turkey points to a gradual build-out of its regional presence. The company’s ability to maintain uninterrupted operations and execute its strategy across multiple markets could remain a key factor influencing sentiment going forward.

Frequently Asked Questions (FAQs)

  1. Why did Memphasys shares remain flat on 20 March 2026?
    Memphasys shares closed unchanged at AUD 0.0050 despite releasing an operational update, suggesting limited immediate market reaction.
  2. What are the key highlights from the update?
    The company reported uninterrupted operations in the MENA region, ongoing demand in Qatar, new orders from the UAE and Iraq, and expansion progress in Egypt and Turkey.
  3. What is driving Memphasys’ growth strategy?
    Memphasys is focused on clinic-level demand generation, expanding into new markets, and building recurring revenue through continued use of the Felix System.